Errata (DOI:10.1016/j.ophtha.2007.03.025);Association between Genetic Polymorphisms of the Prostaglandin F2α Receptor Gene and Response to Latanoprost

Ophthalmology

Volumn 114, Issue 6, 2007, Pages 1039-1045

  Sakurai, Mayumi ^a   Higashide, Tomomi ^a   Takahashi, Mami ^a   Sugiyama, Kazuhisa ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; LATANOPROST; PROSTAGLANDIN F2 ALPHA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA SEQUENCE; DRUG MECHANISM; DRUG RESPONSE; FEMALE; FUSION GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; INTRAOCULAR PRESSURE; INTRON; JAPANESE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 34249696089     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.08.047     Document Type: Erratum

References (43)

1. Aung T., Chew P.T., Yip C.C., et al. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 131 (2001) 636-642
2. Scherer W.J. A retrospective review of non-responders to latanoprost. J Ocul Pharmacol Ther 18 (2002) 287-291
3. Sofowora G.G., Dishy V., Muszkat M., et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther 73 (2003) 366-371
4. Brodde O.E., and Stein C.M. The Gly389Arg beta1-adrenergic receptor polymorphism: a predictor of response to beta-blocker treatment?. Clin Pharmacol Ther 74 (2003) 299-302
5. Martinez F.D., Graves P.E., Baldini M., et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 100 (1997) 3184-3188
6. Evans W.E., and McLeod H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348 (2003) 538-549
7. Sasaki M., Oki T., Iuchi A., et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J Hypertens 14 (1996) 1403-1408
8. Baudin B. Angiotensin II receptor polymorphisms in hypertension: pharmacogenomic considerations. Pharmacogenomics 3 (2002) 65-73
9. Miller J.A., Thai K., and Scholey J.W. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 56 (1999) 2173-2180
10. 1-adrenergic receptor polymorphisms and clinical efficacy of betaxolol hydrochloride in normal volunteers. Ophthalmology 112 (2005) 2131-2136
11. Stjernschantz J., Selen G., Sjoquist B., and Resul B. Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue. Adv Prostaglandin Thromboxane Leukot Res 23 (1995) 513-518
12. Abramovitz M., Boie Y., Nguyen T., et al. Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem 269 (1994) 2632-2636
13. Betz R., Lagercrantz J., Kedra D., et al. Genomic structure, 5′ flanking sequences, and precise localization in 1P31.1 of the human prostaglandin F receptor gene. Biochem Biophys Res Commun 254 (1999) 413-416
14. Vielhauer G.A., Fujino H., and Regan J.W. Cloning and localization of hFP(S): a six-transmembrane mRNA splice variant of the human FP prostanoid receptor. Arch Biochem Biophys 421 (2004) 175-185
15. Ocklind A., Lake S., Wentzel P., et al. Localization of the prostaglandin F2 alpha receptor messenger RNA and protein in the cynomolgus monkey eye. Invest Ophthalmol Vis Sci 37 (1996) 716-726
16. Schlotzer-Schrehardt U., Zenkel M., and Nusing R.M. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci 43 (2002) 1475-1487
17. Mukhopadhyay P., Bian L., Yin H., et al. Localization of EP(1) and FP receptors in human ocular tissues by in situ hybridization. Invest Ophthalmol Vis Sci 42 (2001) 424-428
18. Watanabe T., Nakao A., Emerling D., et al. Prostaglandin F2 alpha enhances tyrosine phosphorylation and DNA synthesis through phospholipase C-coupled receptor via Ca(2+)-dependent intracellular pathway in NIH-3T3 cells. J Biol Chem 269 (1994) 17619-17625
19. Sugimoto Y., Hasumoto K., Namba T., et al. Cloning and expression of a cDNA for mouse prostaglandin F receptor. J Biol Chem 269 (1994) 1356-1360
20. Weinreb R.N., Kashiwagi K., Kashiwagi F., et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 38 (1997) 2772-2780
21. Gaton D.D., Sagara T., Lindsey J.D., et al. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch Ophthalmol 119 (2001) 1165-1170
22. Weinreb R.N., and Lindsey J.D. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci 43 (2002) 716-722
23. Lindsey J.D., Kashiwagi K., Kashiwagi F., and Weinreb R.N. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci 38 (1997) 2214-2223
24. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle: a study on cultured cells and tissue sections. Exp Eye Res 67 (1998) 179-191
25. Toris C.B., Camras C.B., and Yablonski M.E. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 100 (1993) 1297-1304
26. Crowston J.G., Lindsey J.D., Aihara M., and Weinreb R.N. Effect of latanoprost on intraocular pressure in mice lacking prostaglandin FP receptor. Invest Ophthalmol Vis Sci 45 (2004) 3555-3559
27. Zaragoza D.B., Wilson R., Eyster K., and Olson D.M. Cloning and characterization of the promoter region of the human prostaglandin F2alpha receptor gene. Biochim Biophys Acta 1676 (2004) 193-202
28. Excoffier L., and Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 12 (1995) 921-927
29. Stjernschantz J.W. From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan. The Proctor Lecture. Invest Ophthalmol Vis Sci 42 (2001) 1134-1145
30. Rulo A.H., Greve E.L., Geijssen H.C., and Hoyng P.F. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology 103 (1996) 1276-1282
31. Tamada Y., Taniguchi T., Murase H., et al. Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma. J Ocul Pharmacol Ther 17 (2001) 19-25
32. Ezashi T., Sakamoto K., Miwa K., et al. Genomic organization and characterization of the gene encoding bovine prostaglandin F2alpha receptor. Gene 190 (1997) 271-278
33. Neuschafer-Rube F., Moller U., and Puschel G.P. Structure of the 5′-flanking region of the rat prostaglandin F(2alpha) receptor gene and its transcriptional control functions in hepatocytes. Biochem Biophys Res Commun 278 (2000) 278-285
34. Neuschafer-Rube F., Engemaier E., Koch S., et al. Identification by site-directed mutagenesis of amino acids contributing to ligand-binding specificity or signal transduction properties of the human FP prostanoid receptor. Biochem J 371 (2003) 443-449
35. Maxey K.M., Johnson J.L., and LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol 47 suppl (2002) S34-S40
36. Orlicky D.J. Negative regulatory activity of a prostaglandin F2 alpha receptor associated protein (FPRP). Prostaglandins Leukot Essent Fatty Acids 54 (1996) 247-259
37. Van Der Zwaag B., Verzijl H.T., Beltran-Valero de Bernabe D., et al. Mutation analysis in the candidate Mobius syndrome genes PGT and GATA2 on chromosome 3 and EGR2 on chromosome 10. [letter online]. J Med Genet 39 (2002) E30. http://jmg.bmjjournals.com/cgi/content/full/39/6/e30 Available at http://jmg.bmjjournals.com/cgi/content/full/39/6/e30. Accessed June 30, 2002
38. Sipe J.C., Chiang K., Gerber A.L., et al. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci U S A 99 (2002) 8394-8399
39. Rutter J.L., Mitchell T.I., Buttice G., et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 58 (1998) 5321-5325
40. Price S.J., Greaves D.R., and Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276 (2001) 7549-7558
41. Ye S., Watts G.F., Mandalia S., et al. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 73 (1995) 209-215
42. Zhang B., Ye S., Herrmann S.M., et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99 (1999) 1788-1794
43. St Jean P.L., Zhang X.C., Hart B.K., et al. Characterization of a dinucleotide repeat in the 92 kDa type IV collagenase gene (CLG4B), localization of CLG4B to chromosome 20 and the role of CLG4B in aortic aneurysmal disease. Ann Hum Genet 59 (1995) 17-24